Download PDF
Thromb Haemost 2006; 96(06): 698-699
DOI: 10.1160/TH06-11-0631
Editorial Focus
Schattauer GmbH

PAI-1 inhibition in obesity and the metabolic syndrome: A promising therapeutic strategy

Casper G. Schalkwijk
1   Department of Internal Medicine, Division of General Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands
,
Coen D. A. Stehouwer
1   Department of Internal Medicine, Division of General Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 07 November 2006

Accepted 08 November 2006

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35: 93-9.
    CrossrefPubMedGoogle Scholar
  • 2 Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-211.
    CrossrefPubMedGoogle Scholar
  • 3 Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-78.
    CrossrefPubMedGoogle Scholar
  • 4 Alessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inhibitor1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
    CrossrefPubMedGoogle Scholar
  • 5 Kockx M, Leenen R, Seidell J. et al. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost 1999; 82: 1490-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 van Dielen FM, Buurman WA, Hadfoune M. et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004; 89: 4062-8.
    CrossrefPubMedGoogle Scholar
  • 7 Janand-Delenne B, Chagnaud C, Raccah D. et al. Visceral fat as a main determinant of plasminogen activator inhibitor1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-7.
    CrossrefPubMedGoogle Scholar
  • 8 Lijnen HR, Alessi MC, Collen D. et al. Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost 2006; 96: 731-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Elokdah H, Abou-Gharbia M, Hennan JK. et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004; 47: 3491-4.
    CrossrefPubMedGoogle Scholar
  • 10 Crandall DL, Quinet EM, El Ayachi S. et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006; 26: 2209-15.
    CrossrefPubMedGoogle Scholar
  • 11 Crandall DL, Busler DE, McHendry-Rinde B. et al. Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2000; 85: 2609-14.
    CrossrefPubMedGoogle Scholar
  • 12 Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI?. Arterioscler Thromb Vasc Biol 2006; 26: 2183-5.
    CrossrefPubMedGoogle Scholar
  • 13 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-7.
    CrossrefPubMedGoogle Scholar
  • 14 Lijnen HR, Alessi MC, Van Hoef B. et al. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005; 03: 1174-9.
    CrossrefPubMedGoogle Scholar
  • 15 Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-20.
    CrossrefPubMedGoogle Scholar